Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
23andMe Holding Co. ME
$2.02
-$0.08 (-4.05%)
На 18:04, 12 мая 2023
+246.53%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
947580371.00000000
-
week52high
6.31
-
week52low
1.74
-
Revenue
271893000
-
P/E TTM
-3
-
Beta
1.37889100
-
EPS
-0.74000000
-
Last Dividend
0.00000000
-
Next Earnings Date
25 мая 2023 г. в 04:00
Описание компании
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | Outperform | 27 мая 2022 г. |
| Citigroup | Neutral | Neutral | 27 мая 2022 г. |
| Credit Suisse | Outperform | Outperform | 11 февр 2022 г. |
| Citigroup | Neutral | Neutral | 20 дек 2021 г. |
| Citigroup | Neutral | Buy | 15 ноя 2021 г. |
| Cowen & Co. | Outperform | 22 сент 2022 г. | |
| Credit Suisse | Outperform | Outperform | 08 ноя 2022 г. |
| Berenberg | Buy | 29 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| HIBBS KATHY L | D | 235829 | 26259 | 05 дек 2022 г. |
| Hillan Kenneth J. | D | 197162 | 4628 | 20 ноя 2022 г. |
| HIBBS KATHY L | D | 262088 | 4628 | 20 ноя 2022 г. |
| Selsavage Joseph Anthony | D | 277278 | 10105 | 20 ноя 2022 г. |
| SCHELLER RICHARD H | D | 72388 | 18421 | 11 ноя 2022 г. |
| Mohan Neal | A | 90809 | 14633 | 06 сент 2022 г. |
| SCHELLER RICHARD H | A | 90809 | 14633 | 06 сент 2022 г. |
| Chung Patrick S | A | 113034 | 3414 | 06 сент 2022 г. |
| Chung Patrick S | A | 109620 | 14633 | 06 сент 2022 г. |
| BOTHA ROELOF | A | 110561 | 3251 | 06 сент 2022 г. |
Новостная лента
23andMe to Report FY2023 Third Quarter Financial Results
GlobeNewsWire
26 янв 2023 г. в 16:05
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2023 (FY2023) third quarter after the market closes on Wednesday, February 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.
Adding 23andMe To My Tax Loss Basket
Seeking Alpha
26 дек 2022 г. в 02:15
23andMe's stock price has been falling for several years now. But last week's drop seems to me to be driven by tax loss sellers who are indiscriminate about selling price; wanting only to harvest a tax loss for 2022.
23andMe: Strong Genomics Quarter But Cash Burn Is Huge
Seeking Alpha
21 ноя 2022 г. в 10:05
23andMe Holding Co. is a DNA testing company which has genetic information on over 12 million customers. The company announced a strong Q2 FY23, beating both revenue and earnings estimates for growth.
23andme founder on the future of health care
Yahoo Finance
19 ноя 2022 г. в 09:00
This segment originally aired on November 15, 2022. 23andMe Co-Founder and CEO Anne Wojcicki sits down with Yahoo Finance's Anjalee Khemlani at the HLTH conference to discuss the slowdown in growth, consolidation in the health care space, the company's partnership with GSK, drug discovery, and more.
3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240%
PennyStocks
09 ноя 2022 г. в 10:27
Biotech penny stocks with upcoming events to watch in November 2022. The post 3 Biotech Penny Stocks To Watch After MACK Stock Jumps 240% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.